Clinical Trial Update: Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Y-90 ibritumomab tiuxetan after R-CHOP chemotherapy in advanced-stage follicular lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Sunnybrook Health Sciences Centre | Conditions: Follicular Lymphoma | Phase 2 | Status: COMPLETED